当前位置:首页 >财报库 > 报告详情

美德纳Moderna(MRNA)2024年10-K年度报告「NASDAQ」(英文版)(161页).pdf

上传人: Kell****reet 编号:653882 2025-05-20 161页 2.77MB

下载:

1、UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,DC 20549FORM 10-K(Mark One)ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the fiscal year ended December 31,2024OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934

2、For the transition period from _ to _Commission File Number:001-38753Moderna,Inc.(Exact Name of Registrant as Specified in Its Charter)Delaware81-3467528(State or Other Jurisdiction ofIncorporation or Organization)(IRS Employer Identification No.)325 Binney StreetCambridge,Massachusetts02142(Address

3、 of Principal ExecutiveOffices)(Zip Code)(617)714-6500(Registrants Telephone Number,Including Area Code)Securities registered pursuant to Section 12(b)of the Act:Title of each classTrading Symbol(s)Name of each exchange on which registeredCommon stock,par value$0.0001 per shareMRNAThe Nasdaq Stock M

4、arket LLCSecurities registered pursuant to Section 12(g)of the Act:NoneIndicate by check mark if the registrant is a well-known seasoned issuer,as defined in Rule 405 of the Securities Act.Yes No Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Secti

5、on 15(d)of the Act.Yes No Indicate by check mark whether the registrant(1)has filed all reports required to be filed by Section 13 or 15(d)of the Securities Exchange Act of 1934 during the preceding 12 months(or for such shorter period that the registrant was required to file such reports),and(2)has

6、 been subject to such filing requirements for the past 90 days.Yes No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T(232.405 of thischapter)during the preceding 12 months(or for su

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
Moderna是一家领先的mRNA药物公司,通过mRNA技术的进步,重新定义了药物的制作方式,并改变了我们治疗和预防疾病的方式。公司的第一个商业产品Spikevax(COVID疫苗)已帮助数亿全球人民对抗COVID-19。2024年,Moderna成为一家多产品公司,其第二个商业产品mRESVIA(针对老年人的mRNA呼吸道合胞病毒疫苗)获得批准。2024年,Moderna的净产品销售额为31亿美元,主要来自Spikevax的销售。Moderna的平台技术已成功开发出多种疫苗和治疗药物,包括针对COVID-19和RSV的疫苗。公司目前专注于四个产品线:呼吸病毒疫苗、潜伏及其他病毒疫苗、肿瘤治疗药物和罕见病治疗药物。Moderna计划在未来三年内获得十种产品的批准,以推动销售增长并资助下一波研发投资。
新冠疫情对Moderna公司有何影响? Moderna的mRNA平台技术有何优势? Moderna的COVID疫苗和RSV疫苗市场表现如何?
客服
商务合作
小程序
服务号
折叠